We are live on ! Find out more
NBRV

Nabriva Therapeutics plc Ordinary Shares Ireland

Delisted

NBRV was delisted on the 31st of July, 2023.

45 hedge funds and large institutions have $135M invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2017 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

377% more call options, than puts

Call options by funds: $62K | Put options by funds: $13K

80% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 5

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

36% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 14

10% more funds holding

Funds holding: 4145 (+4)

22% less capital invested

Capital invested by funds: $173M → $135M (-$38.4M)

Holders
45
Holders Change
+4
Holders Change %
+9.76%
% of All Funds
1.02%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
19
Increased
9
Reduced
5
Closed
14
Calls
$62K
Puts
$13K
Net Calls
+$49K
Net Calls Change
+$49K
Name Holding Trade Value Shares
Change
Change in
Stake
PA
51
Perceptive Advisors
New York
-$431K -210 Closed
SSA
52
Schonfeld Strategic Advisors
New York
-$410K -200 Closed
CSS
53
Cubist Systematic Strategies
Connecticut
-$348K -170 Closed
Jane Street
54
Jane Street
New York
-$293K -143 Closed
BCM
55
BlueCrest Capital Management
Jersey
-$239K -117 Closed
QT
56
Quantbot Technologies
New York
-$79K -39 Closed
Bank of Montreal
57
Bank of Montreal
Ontario, Canada
-$49K -24 Closed
NFG
58
Next Financial Group
Texas
-$2K -1 Closed
TDC
59
Thompson Davis & Co
Virginia
-$2K -1 Closed

NBRV Hedge Fund Activity: Q4 2017 in Review

45 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q4 2017, worth a combined $135M — down 22% from $173M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new NBRV positions and 14 closed out — a net gain of 5 holders — while 9 added to existing stakes and 5 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $5.49M. The largest seller was Morgan Stanley, cutting an estimated $7.91M.

  • 45 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q4 2017, up from 41 in Q3 2017.
  • Funds reported $135M of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q4 2017, down 22% quarter-over-quarter.
  • 19 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q4 2017 and 14 closed out, a net change of +5 holders.
  • The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q4 2017 was Millennium Management, an estimated $5.49M added.
  • The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q4 2017 was Morgan Stanley, an estimated $7.91M sold.

Based on aggregated 13F filings for Q4 2017.